Dosing underway in study of Cyclacel’s sapacitabine in certain blood cancers

Nano cap Cyclacel Pharmaceuticals (NASDAQ:CYCC) is up 8% premarket on light volume following its announcement that the first patient has been dosed in a Phase 1/2 clinical trial evaluating oral sapacitabine, a nucleoside analogue prodrug, combined with AbbVie’s oral Venclexta (venetoclax), a BCL-2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

The primary endpoint of the 40-subject study is the response rate at year two.

https://seekingalpha.com/news/3479587-dosing-underway-study-cyclacels-sapacitabine-certain-blood-cancers-shares-8-percent-premarket